The activity within Pulse Biosciences, Inc.'s shares (NASDAQ:PLSE) suggests heightened attention from key internal stakeholders regarding the company's valuation and future trajectory. A primary example of this interest is the recent acquisition made by director Robert W. Duggan. On May 11, 2026, Mr. Duggan acquired a substantial stake in the company’s common stock, totaling 660,233 shares at an aggregate value of $12,999,987.
This transaction was executed at a price point of $19.69 per share and utilized Pulse Biosciences' established at-the-market equity offering program. This program is governed by an Equity Distribution Agreement that dates back to February 19, 2026, involving TD Securities (USA) LLC. The purchases were conducted within an open trading window and were compliant with all applicable securities laws, meaning the shares were acquired at the market's prevailing bid price or better when sold.
Since this acquisition, the stock has experienced considerable upward movement, rising to $24.57. This represents a notable gain of nearly 25% from Mr. Duggan's initial purchase price. The company’s shares have demonstrated robust momentum more broadly; year-to-date returns stand at 79%, and the one-year return has reached 49%. The details surrounding these transactions were formally reported via an amended Form 4 filing with the Securities and Exchange Commission on May 15, 2026.
Beyond Mr. Duggan's direct purchases, other senior leadership also participated in recent buying activity. Co-Chairmen of the Board Robert Duggan and Chief Executive Officer Paul LaViolette both purchased a total value of $13.3 million worth of company common stock. This executive purchasing was similarly facilitated through the company’s at-the-market equity offering program during a designated trading window.
In terms of ownership structure, Mr. Duggan's direct holdings in Pulse Biosciences common stock currently amount to 48,370,047 shares. It is important to note that this figure incorporates approximately 700 shares which were inadvertently omitted from the company’s Schedule 14A filing on May 11, 2026.
Furthermore, Mr. Duggan maintains indirect ownership through several affiliated entities. He holds 630,109 shares indirectly via Genius 24C Inc., where he is identified as the sole shareholder. Additionally, another 450,189 shares are held indirectly through Blazon Corporation, an entity in which Mr. Duggan is also the sole owner.
Risks
- Despite positive earnings, concerns were noted regarding the company's overall financial health and increasing expenses.
- The stock is currently trading above what one analysis source determined to be its Fair Value, suggesting potential overvaluation risks.
- Market volatility remains a factor, as evidenced by intraday price movements.
More from Insider Trading
Risks
- Despite positive earnings, concerns were noted regarding the company's overall financial health and increasing expenses.
- The stock is currently trading above what one analysis source determined to be its Fair Value, suggesting potential overvaluation risks.
- Market volatility remains a factor, as evidenced by intraday price movements.